Overview
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta's proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company's lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. The Company's lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.
Basic Stats
The share price of Cabaletta Bio, Inc. as of September 5, 2025 is $1.69 / share. This is an increase of 16.55% from the prior week. The market cap (or net worth) of Cabaletta Bio, Inc. as of September 5, 2025 is $154.55 MM.
The Factor Analysis chart (below right) shows a view of Cabaletta Bio, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 154.55 MM |
| EV | 8.94 MM |
| Shares Out. | 91.45 MM |
| Earnings Date | |
| EPS (TTM) | -1.58 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.57 |
| Short Shares Avail. | 2.10 MM |
| Short Interest | 6.31 MM |
| Short Float | 10.23 % |
| Days to Cover | 3.91 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | -62.78 % |
| Volatility (1 yr) | 1.14 |
| Beta | 2.25 |
| Sharpe Ratio (1 yr) | -0.59 |
| Sortino Ratio (1 yr) | -1.09 |
| PE Ratio | -1.07 |
| Price/Book | 0.87 |
| Price/TBV | 0.87 |
| Book/Market | 1.15 |
| EBIT/EV | -16.14 |
| EBIT(3yr avg)/EV | -10.88 |
| ROA | -0.66 |
| ROE | -0.72 |
| ROIC | -0.71 |
| CROIC | -0.16 |
| OCROIC | -0.51 |
| Implied Volatility | 168.84 % |
| Put/Call OI Ratio | 0.07 |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Cabaletta Bio, Inc. is $11.79. The forecasts range from a low of $2.02 to a high of $23.10. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Cabaletta Bio, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-11-11 | Chardan Capital | Buy | Maintains | |
| 2022-09-14 | Wells Fargo | Overweight | Maintains | |
| 2022-08-30 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2022-08-12 | Chardan Capital | Buy | Maintains | |
| 2022-05-25 | Mizuho | Buy | Maintains | |
| 2022-03-18 | Mizuho | Buy | Maintains | |
| 2022-03-18 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-12-15 | Morgan Stanley | Overweight | Maintains | |
| 2021-12-08 | Wells Fargo | Overweight | Initiate | |
| 2021-06-30 | Mizuho | Buy | Initiate | |
| 2021-03-17 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-01-08 | Chardan Capital | Buy | Initiate | |
| 2020-10-13 | HC Wainwright & Co. | Buy | Initiate | |
| 2020-07-15 | Morgan Stanley | Overweight | Maintains | |
| 2019-11-19 | Morgan Stanley | Overweight | Initiate | |
| 2019-11-19 | Evercore ISI Group | Outperform | Initiate | |
| 2019-11-19 | Cowen & Co. | Outperform | Initiate | |
| 2023-01-27 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2023-02-17 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-01-03 | Wells Fargo | Overweight | Maintains | |
| 2023-03-17 | HC Wainwright & Co. | Buy | Maintains | |
| 2023-03-17 | Mizuho | Buy | Reiterate | |
| 2023-03-22 | Chardan Capital | Buy | Reiterate | |
| 2023-04-03 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-04-10 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-05-03 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-05-17 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-05-12 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-10-04 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-11-10 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-11-15 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2023-08-14 | Guggenheim | Buy | Buy | Reiterate |
| 2023-09-05 | Citigroup | Buy | Initiate | |
| 2023-11-29 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-10-24 | Cantor Fitzgerald | Overweight | Initiate | |
| 2023-09-18 | Wells Fargo | Overweight | Overweight | Maintains |
| 2023-11-08 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2023-07-18 | Guggenheim | Buy | Initiate | |
| 2023-08-11 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-10-19 | Stifel | Buy | Initiate | |
| 2023-11-29 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2024-02-05 | Jefferies | Buy | Initiate | |
| 2024-05-24 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-04-04 | Citigroup | Buy | Buy | Maintains |
| 2024-05-16 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-03-22 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-03-22 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-03-22 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-04-05 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-06-21 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-06-17 | Stifel | Buy | Buy | Maintains |
| 2024-06-14 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-09 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-12-19 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| 2025-05-16 | Guggenheim | Buy | Buy | Maintains |
| 2025-05-16 | Citigroup | Buy | Buy | Maintains |
| 2024-11-15 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-11-15 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-17 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-18 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-12 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2024-08-12 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-12-20 | Evercore ISI Group | Outperform | In-Line | Downgrade |
| 2024-10-10 | UBS | Buy | Initiate | |
| 2025-05-15 | Guggenheim | Buy | Buy | Maintains |
| 2025-01-17 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-08-08 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2025-02-18 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-04-01 | UBS | Buy | Buy | Maintains |
| 2025-04-01 | Guggenheim | Buy | Buy | Reiterate |
| 2025-04-01 | Wells Fargo | Equal-Weight | Equal-Weight | Maintains |
| 2025-04-01 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2025-04-01 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-06-11 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-09-05 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
